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Supplementary Figure 1. Isolation of human prefrontal cortex neurons by flow cytometry. (a) 
Representative gating image for flow cytometry sorting of neuronal (NeuN+) and glial/non-
neuronal (NeuN–) nuclei, after gating for 7-AAD positive nuclei. (b) Reanalysis of NeuN+ 
aliquots after sorting show a high purity for NeuN+ stained nuclei (on average 96%). (c) mRNA-
qPCR analysis confirming the purity of our neuronal and glial isolations. MAP2 and SYT1 are 
neuronal markers, whereas OLIG2 and GFAP are glial markers (+ and – refers to NeuN+ and 
NeuN–, respectively). The control RPL37 is located in both neurons and glia. Analysis of an 
aliquot of 1,000 NeuN+ and NeuN– nuclei prepared in RNase inhibitor (Superase, Thermo 
Fisher Scientific), and cDNA conversion and qPCR amplification done with the Power SYBR 










Supplementary Figure 2. Analysis of cytosine site coverage and sample distributions showing 
high technical reproducibility. (a) Density plots showing read coverage at CpG (left) and CpH 
(right) for each individual sample. Red dotted line shows 30× coverage. (b) Density plots 
showing methylation distribution at CpG (left) and CpH (right) with ≥30× coverage for each 





methylation. Pearson’s correlation of methylation for the 10,000 most variable CpG and CpH 
sites. Technical replicates (TR, library preparation replicated for select DNA samples) and 
sequencing replicates (SR, sequencing replicated across lanes/flow cells for select libraries) are 
shown in green and blue colors, respectively. The average correlation scores for SR is 0.998; for 
TR is 0.976; for all the other unique biological samples is 0.967, as determined by Pearson’s 
correlation of all CpG and CpH methylation sites. (d) Averaged % methylation for each type of 
CpH site across all samples. Both significant differentially methylated Cs in AD and 1.2M 
background Cs are shown. Enhancer regions in neurons in this study had a similar distribution of 








Supplementary Figure 3. Neuronal subtypes in the neuronal nuclei fraction (NeuN+) isolated 
from the prefrontal cortex of individuals with no/mild, moderate, and severe AD pathology 
(Braak stage 1-2, 3-4, and 5-6, respectively). (a) Proportion of glutamate neurons in each of the 
Braak stage groups. The relative abundance of glutamate vs GABA neurons in the NeuN+ 
fraction was calculated by neuronal subtype deconvolution, using neuron subtype specific 
markers (n=1,144 cytosine sites). This analysis indicated that the majority of neuronal nuclei 
isolated from the prefrontal cortex were glutamatergic (88.56%). There was no difference in 





by 3-way ANOVA. The average percentage of glutamate proportion for Braak 1-2 is 0.892; 
Braak 3-4 is 0.885; Braak 5-6 is 0.878. The boxplot center line is the median, the lower and 
upper limits are the first and third quartiles (25th and 75th percentiles), and the whiskers are 1.5× 
the interquartile range. (b) Proportion of 21 specific types of neurons in NeuN+ fractions of 
Braak stage groups. Each specific neuronal type is averaged for each Braak stage group. 
Glutamatergic neuronal types highlighted in blue and GABAergic neuronal types highlighted in 
pink. Averaged % neuronal subtype proportion ± s.e.m. Neuronal proportions were similar to as 
previously described1, and there was no significant differences between Braak stage groups for 









Supplementary Figure 4. Genomic locations of neuronal enhancers and promoters significantly 
associated with AD pathology. Log2(FC) refers to log fold change in enrichment of genomic 
location with differentially methylated enhancer/promoter cytosines. In AD, differentially 
methylated cytosines in enhancers/promoters were enriched in intergenic and coding exons. 










Supplementary Figure 5. DSCAML1 enhancers exhibit DNA methylation changes that occur 
early in AD. In prefrontal cortex neurons, DNA methylation differences at enhancers and 
promoters were analyzed in individuals that did not yet have neurofibrillary tangle pathology in 
the prefrontal cortex (Braak stage 1-4). In DSCAML1 intron 3 there were 5 sites with significant 
DNA methylation changes occurring prior to the arrival of tangle pathology. –log10(P) refers to 
the significance of differentially methylated cytosine enrichment at enhancers, with the sign 
corresponding to the direction of methylation change (hyper or hypomethylated). Differentially 
methylated enhancers in advanced AD (Braak stage 1-6) are also noted by red dots. Tracks for 
neuronal (NeuN+) H3K27ac and H3K4me3, from PsychENCODE (pink, n=9 individuals) are 









Supplementary Figure 6. Interaction network of proteins with differential regulation in AD 
neurons. Two independent datasets were overlapped: 1) gene targets of enhancers with DNA 
methylation abnormalities in AD cortical neurons, and 2) proteomic changes in laser captured 
cortical neurons in AD2. 109 genes had both a differentially methylated enhancer and proteomic 
abnormality in AD neurons (genes identified in the two datasets significantly overlapped, p<10-5, 
hypergeometric test). Image showing protein-protein interaction network, as determined by 
DAPPLE, for proteins affected in AD neurons in both datasets (proteomic and epigenetic 













Supplementary Figure 7. The contribution of sources of variation in the RNA-Seq data. (a) Bar 
plot showing variance fractions for 10 example genes. (b) Violin plot depicting the contribution 
of each factor to total variance. On average 10.8% ± 0.078%, 10.6% ± 0.076%, 11.6% ± 0.097%, 
8.9% ± 0.067%, 4.7% ± 0.039%, 2.8% ± 0.030% of total RNAseq variance was explained by 
Braak stage, RIN, neuronal proportion, postmortem interval, sex, and age, respectively 





and third quartiles (25th and 75th percentiles), and the whiskers are 1.5× the interquartile range. 
(c) The relationship between enhancer DNA methylation changes and target gene expression 
changes with AD pathology. Our DNA methylation and corresponding RNA-seq data (n=25 
individuals) was used to examine enhancers with DNA methylation status significantly 
(significant DMR) or non-significantly (non-significant DMR) associated with AD pathology. 
AD-associated enhancers exhibited DNA methylation changes with AD Braak stage that were 
inversely correlated to target gene expression changes with AD Braak stage (p<0.001, Pearson's 
correlation). AD-associated enhancers showed a greater relationship between DNA methylation 
and gene expression changes in AD, than enhancers not associated with AD (p<0.001, Fisher r-
to-z transformation). Correlation line with 95% confidence interval shown of data for n=1,794 










Supplementary Figure 8. Network analysis integrating epigenetic, transcriptomic, and 
proteomics data identifies pathways involved in AD. The OmicsIntegrator3 was used to combine 
three omics datasets identifying changes in AD cortical neurons: differentially methylated 
enhancer data, differential gene expression data, and proteomics data. A high-confidence 
network relevant to AD was identified with UBC as the focal gene hub. Pathway analysis by 
MetaCore revealed a significant enrichment in cell cycle, inflammation, and amyloid 







Supplementary Figure 9. Correlation between DNA methylation at cytosine site within 
enhancer targeting BACE1 (chr11: 117,625,228) and BACE1 mRNA levels. Analysis comparing 
DNA methylation status to BACE1 mRNA expression was adjusted for sex, age, postmortem 
interval, neuronal proportion, and RIN. Enhancers that target BACE1 in our Hi-C analysis were 
examined. The same enhancer with the cytosine (cg07533617; Fig. 4) from the ROSMAP 
analysis contained a site (chr11:117,625,228; 5.51% hypomethylation in AD) at which loss of 
DNA methylation was significantly associated with increased BACE1 mRNA expression 
(q<0.05, robust linear regression). Correlation between residuals of DNA methylation (beta 








Supplementary Figure 10. DNA methylation at DSCAML1 intron 3 is associated with BACE1 
gene expression in early disease, and to the pathology and cognitive symptoms of AD. (a) 
Correlation between DNA methylation at DSCAML1 intron 3 (average of 22 CpG sites) and 





methylation was correlated with BACE1 expression in the prefrontal cortex in early disease 
stages (Braak ≤4, p<0.001, robust linear regression model), but no longer in late stage AD 
(n=101 and 76 AD patients, respectively). Analysis performed using the ROSMAP dataset, 
which contained AD patients with both transcriptomic data generated by RNA-seq and genome-
wide DNA methylation data generated by 450K Illumina DNA methylation arrays. (b) 
Significance of correlation between averaged DNA methylation at DSCAML1 intron 3 and AD 
pathology/cognitive symptoms. Analysis used the ROSMAP DNA methylation and 
pathological/clinical data (n=465 AD and controls). DNA hypomethylation at DSCAML1 intron 
3 was significantly correlated with increased amyloid pathology and the decline in perceptual 
speed (*p<0.05, linear mixed model with annual cognitive measures as the longitudinal 
outcomes and DNA methylation as the predictor). (a, b) All analyses of ROSMAP data are 









Supplementary Figure 11. The effect of genetic variation within DSCAML1 intron 3 enhancers 
on transcript levels of nearby genes (BACE1, CEP164, and DSCAML1) in the prefrontal cortex 
(n=278 AD and control individuals in ROSMAP dataset). Analysis of haplotype association with 
gene expression that controlled for age, sex, postmortem interval, years of education, Braak 
stage, RIN, and neuronal proportion, was performed on the genomic area surrounding DSCAML1 
intron 3 (chr11:117,000,000-117,800,000, genomic area centered on DSCAML1 intron 3; n=34 
haplotypes identified using 4,305 SNPs). Each blue track shows the significance of the haplotype 









Supplementary Figure 12. CpG and CpH methylation profiles at enhancers in aging neurons. 
(a) % CpG (left) and CpH (right) methylation status from infancy to adulthood in healthy 
neurons. Methylation status at CpG and CpH sites in enhancers relevant to AD were examined in 
whole-genome bisulfite sequencing data from ref4, with a 1× methylated read threshold (n=1 
individual per age point). As previously reported4, CpG methylation remained relatively stable 
across ages, while CpH methylation in neurons showed a 2.01-fold increase in early life. (b) At 
AD enhancers, levels of CpG methylation decreased in neurons of older normal adults (no/mild 





n=38 individuals; 3-4 n=32; 5-6 n=31; p<0.001 for Braak stage 1-2, robust linear regression 
model). Age analysis was performed on CpG sites (n=531 CpGs) in enhancers relevant to AD 
(n=848 enhancers showing both epigenetic and associated gene transcript differences in AD, as 
identified in omics integration analysis). Analysis of % CpG methylation change with age, 
adjusted for sex, postmortem interval, and neuronal proportion. Data generated by the bisulfite 






Supplementary Table 1. Clinical and demographic information for investigated samples 
Braak groupƚ Sex Age PMI Female Male 
Braak 1-2 (n=38) 17 21 82.55 ± 1.78 44.91 ± 2.85 
Braak 3-4 (n=32) 16 16 84.72 ± 1.53 45.75 ± 3.57 
Braak 5-6 (n=31) 14 17 81.87 ± 1.42 41.65 ± 3.42 








Supplementary Table 2. Genome-wide significant differentially methylated cytosines in ADƚ. 
ƚDifferentially methylated cytosine sites (individual CpGs and CpHs) corresponding to the severity of 
tangle pathology (Braak stage), after controlling for age, sex, postmortem interval, and neuronal subtype; 
q<0.05, robust linear regression model. 
ǂLocated in enhancer at DSCAML1 intron 3 
  
chr loc strand type seq logFC t p-value q-value B 
chr3 184147761 - CG CGG -0.15 -6.42 5.35E-09 6.46E-03 9.25 
chr2 3149222 - CHH CAC -0.24 -6.18 1.54E-08 9.31E-03 8.39 
chr6 107988290 - CG CGC 0.13 6.06 2.64E-08 9.77E-03 7.93 
chr8 145165716 - CHH CAC -0.13 -6.00 3.49E-08 9.77E-03 7.66 
chr21 38183814 + CG CGA 0.11 5.97 4.05E-08 9.77E-03 7.53 
chr1 44471534 - CHH CCT -0.24 -5.84 7.18E-08 1.37E-02 7.07 
chr11ǂ 117434522 + CHH CAC -0.06 -5.82 7.96E-08 1.37E-02 7.03 
chr3 14584915 + CG CGG 0.16 5.66 1.59E-07 2.39E-02 6.34 
chr12 124975467 - CHG CTG -0.22 -5.61 2.01E-07 2.70E-02 6.14 
chr7 111799521 - CHG CAG -2.67 -5.50 3.23E-07 3.77E-02 5.85 
chr5 149652997 - CHH CTA -0.34 -5.48 3.43E-07 3.77E-02 5.63 
chr22 48915491 - CG CGA 0.15 5.44 4.01E-07 4.04E-02 5.66 





Supplementary Table 3. Epigenetic disruption of genes identified by AD GWAS 
SNP id Chromosome Location Annotated gene Most significant DMR associated with gene 
rs6656401 1 207692049 CR1  
rs6733839 2 127892810 BIN1 
chr2:127827386-127829645; 
hypomethylated; q=1.30E-03 
rs35349669 2 234068476 INPP5D  
rs190982 5 88223420 MEF2C 
chr5:87847668-87848509; 
hypomethylated; q=9.11E-03 




rs10948363 6 47487762 CD2AP  
rs2718058 7 37841534 NME8  
rs1476679 7 100004446 ZCWPW1  
rs11771145 7 143110762 EPHA1  
rs28834970 8 27195121 PTK2B  
rs9331896 8 27467686 CLU  
rs10838725 11 47557871 CELF1  
rs983392 11 59923508 MS4A6A  
rs10792832 11 85867875 PICALM  
rs11218343 11 121435587 SORL1 
chr11:121443047-121443147; 
hypermethylated; q=2.98E-02 
rs17125944 14 53400629 FERMT2  




rs8093731g 18 29088958 DSG2  
rs4147929 19 1063443 ABCA7  
rs3865444g 19 51727962 CD33  
rs7274581 20 55018260 CASS4  





















Supplementary Table 4. Differentially expressed DMRs with detectable eRNAs levels. 
  chr loc1 loc2 logFC t p-value q-value B 
chr1 4762751 4764047 0.260 4.326 2.42E-04 2.79E-02 0.073 
chr1 4834309 4835632 0.186 3.673 1.24E-03 4.60E-02 -0.879 
chr5 14710706 14711092 0.150 3.841 8.16E-04 4.10E-02 -0.493 
chr6 35025997 35027668 0.160 3.860 7.77E-04 4.05E-02 -0.458 
chr6 163986982 163987077 -0.262 -3.800 9.02E-04 4.25E-02 -0.746 
chr7 28811076 28812124 -0.314 -3.645 1.33E-03 4.71E-02 -1.400 
chr7 44272710 44273472 0.300 3.756 1.01E-03 4.39E-02 -1.066 
chr7 157394382 157395000 0.251 3.775 9.61E-04 4.32E-02 -1.073 
chr7 158253410 158255115 0.181 3.688 1.19E-03 4.50E-02 -0.852 
chr8 145813688 145816526 0.207 3.719 1.10E-03 4.43E-02 -0.854 
chr9 124537337 124538703 0.272 3.948 6.25E-04 3.75E-02 -0.479 
chr9 132686066 132687101 -0.187 -3.936 6.43E-04 3.82E-02 -0.284 
chr9 138676950 138677850 0.298 4.415 1.93E-04 2.56E-02 0.692 
chr9 140777461 140778562 0.190 3.805 8.91E-04 4.25E-02 -0.626 
chr10 123258453 123261133 -0.224 -3.731 1.07E-03 4.40E-02 -0.772 
chr11 13379017 13379596 0.359 4.439 1.82E-04 2.52E-02 -0.047 
chr11 113978817 113980939 0.151 3.776 9.57E-04 4.32E-02 -0.637 
chr12 111712396 111713562 0.363 4.718 9.02E-05 2.03E-02 0.750 
chr12 123561676 123563254 0.302 3.966 5.96E-04 3.72E-02 -0.483 
chr12 131056904 131059213 0.202 3.613 1.43E-03 4.89E-02 -1.055 
chr13 113625075 113625886 0.325 5.824 5.81E-06 1.48E-02 2.934 
chr14 93422062 93423490 0.215 3.998 5.51E-04 3.66E-02 -0.360 
chr16 9979424 9979700 0.301 4.323 2.44E-04 2.79E-02 -0.445 
chr17 1918685 1919074 0.326 3.635 1.36E-03 4.76E-02 -1.369 
chr17 77075771 77076892 0.362 3.702 1.15E-03 4.45E-02 -1.289 
chr17 77393769 77394251 0.333 3.902 7.00E-04 3.96E-02 -0.730 
chr17 77409547 77411708 0.329 4.302 2.57E-04 2.82E-02 0.460 
chr17 77454073 77455189 0.293 3.752 1.02E-03 4.39E-02 -0.729 
chr17 77461230 77462123 0.330 3.597 1.49E-03 4.93E-02 -1.057 
chr17 77529375 77531687 0.284 4.149 3.77E-04 3.15E-02 0.158 
chr17 77537049 77541580 0.293 4.058 4.74E-04 3.42E-02 -0.006 
chr18 70304677 70305411 0.342 3.940 6.37E-04 3.79E-02 -0.313 
chr21 45748293 45749727 0.257 4.196 3.36E-04 3.09E-02 0.126 
chr22 31151672 31151997 0.361 3.768 9.76E-04 4.33E-02 -1.222 
chr22 31272039 31275558 0.253 4.261 2.85E-04 2.90E-02 0.308 





Supplementary Table 5. Pathway analysis† for networks identified by OmicsIntegrator 
 Process networks p-value q-value 
UBC 
Inflammation_MIF signaling 2.19E-10 3.41E-08 
DNA damage_Checkpoint 3.15E-09 2.46E-07 
Cell cycle_G1-S 5.95E-09 3.11E-07 
Cell cycle_G0-G1 1.37E-08 5.35E-07 
Inflammation_Protein C signaling 2.40E-07 7.50E-06 
Cell cycle_G1-S Interleukin regulation 7.17E-07 1.86E-05 
Immune response_BCR pathway 2.07E-06 4.61E-05 
Reproduction_FSH-beta signaling pathway 5.72E-06 1.12E-04 
Cell cycle_G1-S Growth factor regulation 1.05E-05 1.82E-04 
Signal Transduction_TGF-beta, GDF and Activin signaling 1.19E-05 1.83E-04 
CUL3 
Cell cycle_G1-S Growth factor regulation 5.66E-11 7.86E-09 
Signal transduction_ESR1-membrane pathway 4.15E-10 2.89E-08 
Reproduction_Progesterone signaling 1.35E-07 6.25E-06 
Apoptosis_Anti-Apoptosis mediated by external signals via 
PI3K/AKT 
3.86E-07 1.34E-05 
Cardiac development_FGF_ErbB signaling 1.48E-06 3.65E-05 
Signal transduction_Androgen receptor signaling cross-talk 1.58E-06 3.65E-05 
Translation_Regulation of initiation 1.84E-06 3.65E-05 
Reproduction_Feeding and Neurohormone signaling  4.82E-06 8.38E-05 
Signal transduction_WNT signaling 5.57E-06 8.61E-05 
Signal transduction_ESR1-nuclear pathway 6.45E-06 8.97E-05 






Supplementary Table 6. Disease enrichment† for networks identified by OmicsIntegrator 
 Disease p-value q-value 
UBC 
Lymphoma 3.21E-23 5.73E-20 
Pathological Conditions, Signs and Symptoms 8.11E-22 7.22E-19 
Virus Diseases 5.04E-21 2.99E-18 
Mental Disorders 1.99E-19 7.42E-17 
RNA Virus Infections 2.65E-19 7.42E-17 
Psychiatry and Psychology 2.81E-19 7.42E-17 
Pathologic Processes 2.92E-19 7.42E-17 
Chemically-Induced Disorders 9.67E-19 2.15E-16 
Drug-Related Side Effects and Adverse Reactions 1.35E-18 2.60E-16 
In-house Adverse Events 1.46E-18 2.60E-16 
CUL3 
Amyloid Neuropathies, Familial 1.21E-28 4.03E-26 
Pharmacological Phenomena 1.36E-28 4.03E-26 
Pharmacological and Toxicological Phenomena 1.36E-28 4.03E-26 
Drug Resistance 1.36E-28 4.03E-26 
Amyloid Neuropathies 6.44E-28 1.53E-25 
Thyroid Carcinoma, Papillary 6.04E-25 1.19E-22 
Myopathy, Myofibrillar 2.20E-23 3.72E-21 
Nerve Sheath Neoplasms 4.19E-23 6.21E-21 
Aneuploidy 5.05E-23 6.64E-21 
Peripheral Nervous System Diseases 1.04E-22 1.23E-20 








Supplementary Table 7. Differentially expressed genes in the AD prefrontal cortex that were 
identified both in this study and the ROSMAP study by RNA-sequencing 
Gene ROSMAP RNA-Seq Study RNA-Seqǂ 
Gene 
symbol Gene Location p-value
ƚ p-valueƚ 
ABTB2 chr11:34172535-34379555 4.15E-03 1.02E-04 
ACP1 chr2:264140-278283 1.56E-03 7.56E-04 
ADAMTS2 chr5:178537852-178772431 1.52E-04 4.64E-04 
ADORA2A chr22:24813847-24838328 4.75E-04 2.51E-03 
AGFG2 chr7:100136834-100165842 1.23E-04 1.08E-03 
AIFM3 chr22:21319396-21335649 2.70E-05 1.85E-03 
AIG1 chr6:143381633-143661441 4.72E-03 9.39E-04 
ALDH5A1 chr6:24495080-24537435 3.17E-03 2.25E-03 
AMN1 chr12:31824071-31882108 2.03E-03 2.83E-04 
AMPD2 chr1:110158726-110174673 4.62E-03 2.45E-03 
AMZ2P1 chr17:62962668-62971694 7.78E-04 1.99E-04 
ARHGEF10L chr1:17866330-18024369 2.37E-03 3.91E-04 
ARMC10 chr7:102715328-102740205 4.49E-03 5.19E-05 
ARPP19 chr15:52839242-52862080 1.75E-03 3.82E-04 
ASAH1 chr8:17913934-17942494 9.95E-04 2.93E-03 
ATAD1 chr10:89511269-89601100 1.00E-03 1.31E-03 
BEX2 chrX:102564274-102565974 2.51E-03 2.66E-03 
BTF3L4 chr1:52521797-52556388 3.85E-03 4.28E-05 
CCDC88C chr14:91737667-91884188 2.82E-03 1.53E-03 
CIC chr19:42772689-42799949 1.23E-05 1.29E-03 
CMTM3 chr16:66637777-66647795 3.80E-04 2.59E-04 
COL27A1 chr9:116917840-117074791 3.45E-06 1.62E-06 
COPS8 chr2:237993955-238009109 2.64E-03 3.75E-04 
COX18 chr4:73921797-73935472 1.25E-03 2.04E-03 
CSNK2A1 chr20:459116-524465 1.41E-03 2.11E-03 
CXXC1 chr18:47808713-47814674 4.57E-03 2.01E-03 
CYP2J2 chr1:60358980-60392462 1.16E-03 2.06E-03 
DAB2IP chr9:124329336-124547809 1.34E-05 9.66E-05 
DCAF16 chr4:17802278-17812381 2.35E-03 4.09E-04 
DGKG chr3:185823457-186080026 1.76E-03 1.24E-04 
DNAJC10 chr2:183580999-183659191 1.62E-04 8.21E-04 
DNAJC18 chr5:138744279-138780180 1.81E-03 2.76E-03 
DYNC2LI1 chr2:44001178-44037149 2.95E-03 1.33E-03 
DYNLT3 chrX:37696010-37706890 1.20E-03 2.06E-05 
E2F4 chr16:67226072-67232821 1.57E-03 9.20E-04 
FBXO2 chr1:11708424-11715842 2.18E-06 2.01E-03 
FIZ1 chr19:56102746-56113336 4.05E-03 2.58E-05 
FURIN chr15:91411822-91426688 9.18E-06 2.47E-03 
GIT1 chr17:27900487-27921072 1.41E-04 2.08E-03 
GK chrX:30671476-30748725 2.41E-04 4.87E-04 
GNA12 chr7:2767746-2883958 4.06E-03 1.81E-03 
GOLT1B chr12:21654715-21671342 2.54E-03 4.35E-06 
HIRA chr22:19318221-19435224 4.36E-05 2.75E-03 
HOMER3 chr19:19040010-19052070 2.20E-03 2.46E-03 
HPRT1 chrX:133594183-133654543 1.45E-03 1.09E-04 
HS1BP3 chr2:20760208-20850849 3.78E-03 1.97E-03 
HS6ST1 chr2:128994290-129076151 9.95E-04 5.14E-04 
HSD11B2 chr16:67464555-67471456 1.33E-04 5.13E-04 
HSPB2 chr11:111782966-111789574 2.64E-05 2.24E-04 





ITFG1 chr16:47188298-47498060 1.92E-03 1.31E-04 
JUND chr19:18390563-18392432 1.51E-04 6.87E-04 
KATNBL1 chr15:34432875-34502297 2.89E-03 1.53E-04 
KCNH3 chr12:49932940-49952091 2.91E-03 2.13E-03 
KIFC3 chr16:57792129-57896957 1.41E-03 8.76E-04 
LRRC4B chr19:51020149-51071302 3.13E-03 9.00E-04 
LYRM7 chr5:130506503-130541119 8.50E-05 1.26E-03 
MAP2K3 chr17:21187984-21218552 2.75E-05 1.23E-03 
NDUFA5 chr7:123177051-123198309 6.91E-04 5.22E-05 
NEU3 chr11:74699179-74729938 2.42E-03 1.35E-03 
NUDT21 chr16:56463045-56486111 2.15E-03 1.88E-05 
OCIAD1 chr4:48807229-48863834 3.23E-03 1.83E-03 
ORAI2 chr7:102073553-102097268 2.80E-03 1.40E-03 
PCCB chr3:135969148-136056738 2.33E-03 6.74E-05 
PFN2 chr3:149682691-149768575 1.24E-03 8.69E-05 
PLXNB2 chr22:50713408-50746056 1.90E-03 3.02E-03 
PURG chr8:30853321-30891231 9.07E-04 7.52E-04 
RAPGEF1 chr9:134452157-134615461 2.09E-03 8.49E-04 
RBM38 chr20:55966463-55984389 3.66E-04 2.66E-03 
SALL2 chr14:21989232-22005350 1.91E-04 2.82E-03 
SCRIB chr8:144873090-144897549 1.20E-03 1.24E-03 
SETD1A chr16:30968615-30996437 3.56E-04 6.98E-04 
SLC25A40 chr7:87462883-87505672 2.02E-03 8.38E-05 
SLC4A11 chr20:3208063-3219836 1.88E-07 1.89E-03 
SMIM15 chr5:60453536-60458301 7.88E-04 1.88E-03 
SMTN chr22:31460091-31500743 3.03E-03 1.22E-03 
SPECC1L chr22:24666786-24813708 1.05E-04 7.30E-05 
SRCAP chr16:30709530-30755602 9.94E-05 2.31E-03 
SRRT chr7:100472733-100486285 1.36E-03 2.79E-04 
SSBP2 chr5:80708840-81047616 4.13E-03 1.67E-03 
TATDN2 chr3:10289707-10322902 4.53E-03 2.08E-03 
TFCP2 chr12:51487446-51566926 2.10E-03 1.23E-03 
TFDP2 chr3:141663277-141868386 2.22E-03 2.32E-03 
TM6SF1 chr15:83776159-83813606 4.36E-03 3.11E-03 
TMA16 chr4:164415594-164441691 3.86E-03 2.73E-03 
TMEM14B chr6:10747992-10852986 2.38E-03 2.60E-03 
TNIP1 chr5:150409506-150473138 9.91E-05 3.43E-04 
TRPC1 chr3:142442916-142526730 4.65E-04 1.07E-04 
UCHL5 chr1:192981380-193029237 7.34E-04 2.98E-03 
USF2 chr19:35759881-35770724 4.62E-03 2.15E-03 
VAV3 chr1:108113782-108507766 1.19E-04 9.40E-04 
VPS29 chr12:110928902-110939922 4.00E-03 1.31E-03 
VWA5B2 chr3:183948217-183960117 2.89E-05 9.76E-04 
XKR8 chr1:28285973-28294607 2.83E-04 4.69E-04 
ZBED1 chrX:2404455-2419008 3.60E-06 7.00E-04 
ZMYND8 chr20:45837859-45985567 7.78E-05 1.73E-04 
ZNF219 chr14:21558205-21572881 1.19E-04 1.72E-03 
ZNF358 chr19:7580178-7585912 9.96E-04 2.03E-03 
ZNF385A chr12:54762917-54785082 2.20E-03 1.78E-03 
ZNF441 chr19:11877815-11894893 5.58E-04 1.18E-03 
ZNF768 chr16:30535325-30538142 2.82E-03 2.21E-03 
ZRANB2 chr1:71528974-71546980 1.03E-03 6.43E-04 
ƚall differentially expressed genes are q<0.05, robust linear regression model. Genes are differentially expressed with 
AD pathology after controlling for age, sex, postmortem interval, RIN, neuronal proportion, and in ROSMAP data, 
years of education 






Supplementary Table 8. Correlation between DNA methylation at cytosine in enhancers 
targeting BACE1 and BACE1 gene expression. 
 
ƚenhancer site shown in Supplementary Fig. 9. 
  
chr loc strand type seq p-value coefficients q-value 
chr11 117609126 - CG CGT 4.93E-01 0.255 7.39E-01 
chr11 117609150 - CG CGT 6.33E-02 0.731 2.85E-01 
chr11 117609170 - CG CGT 2.28E-01 0.421 4.44E-01 
chr11 117609208 - CHH CAT 3.17E-02 0.723 2.28E-01 
chr11 117609223 - CHG CTG 9.97E-01 -0.009 9.97E-01 
chr11 117609229 - CHH CAT 1.64E-01 0.479 4.18E-01 
chr11 117609258 - CHH CAC 2.66E-02 1.030 2.28E-01 
chr11 117609260 - CHH CAC 1.06E-01 0.684 3.94E-01 
chr11 117625155 - CG CGA 4.81E-02 1.005 2.48E-01 
chr11 117625157 - CHH CAC 4.78E-02 0.975 2.48E-01 
chr11 117625158 - CHH CCA 1.81E-01 16.039 4.18E-01 
chr11 117625159 - CHH CCC 6.15E-01 -2.325 8.12E-01 
chr11 117625171 - CHH CCT 9.47E-01 -0.161 9.74E-01 
chr11 117625177 - CHG CTG 6.25E-01 -2.531 8.12E-01 
chr11 117625181 - CG CGA 6.86E-01 0.235 8.23E-01 
chr11 117625182 - CHG CCG 3.20E-01 4.216 5.46E-01 
chr11 117625183 - CHH CCC 6.32E-01 1.301 8.12E-01 
chr11 117625192 - CHG CTG 8.27E-01 -0.168 9.05E-01 
chr11 117625196 - CHH CCC 6.59E-01 1.204 8.18E-01 
chr11 117625213 - CHH CAT 4.77E-01 0.323 7.39E-01 
chr11 117625219 - CHH CTC 1.44E-01 -0.939 4.18E-01 
chr11ƚ 117625228 - CHH CAC 3.23E-03 -1.100 4.93E-02 
chr11 117625255 - CHH CTC 1.09E-01 0.650 3.94E-01 
chr11 117625259 - CHH CCT 3.19E-01 4.117 5.46E-01 
chr11 117625261 - CHH CAC 8.97E-01 0.052 9.49E-01 
chr11 117625286 - CHH CCC 5.48E-01 4.775 7.89E-01 
chr11 117642665 + CHG CAG 4.11E-03 -15.535 4.93E-02 
chr11 117642675 + CHH CCC 1.73E-01 -21.583 4.18E-01 
chr11 117642676 + CHH CCT 3.33E-01 11.427 5.46E-01 
chr11 117642679 + CHH CCT 1.38E-01 4.800 4.18E-01 
chr11 117642690 + CHG CAG 1.86E-01 -3.045 4.18E-01 
chr11 117642720 + CHG CAG 7.27E-01 0.406 8.44E-01 
chr11 117642731 + CHG CAG 2.35E-01 -1.537 4.44E-01 
chr11 117642736 + CHH CTC 2.01E-01 0.859 4.26E-01 
chr11 117642739 + CHG CAG 1.09E-04 2.285 3.91E-03 







Isolation of neuronal nuclei by flow cytometry 
Neuronal nuclei were separated using a flow cytometry-based approach, similar to as previously 
described5, 6. Human brain tissue (250 mg) for each sample was minced in 2 mL PBSTA (0.3 M 
sucrose, 1X phosphate buffered saline (PBS), 0.1% Triton X-100). Samples were then 
homogenized in PreCellys CKMix tubes with a Minilys (Bertin Instruments) set at 3,000 rpm for 
three 5 sec intervals, 5 min on ice between intervals. Samples homogenates were filtered through 
Miracloth (EMD Millipore), followed by a rinse with an additional 2 mL of PBSTA. Samples 
were then place on a sucrose cushion (1.4 M sucrose) and nuclei were pelleted by centrifugation 
at 4,000 × g for 30 min 4°C using a swinging bucket rotor. For each sample, the supernatant was 
removed and the pellet was incubated in 700 μl of 1X PBS on ice for 20 min. The nuclei were 
then gently resuspended and blocking mix (100 μl of 1X PBS with 0.5% BSA (Thermo Fisher 
Scientific) and 10% normal goat serum (Gibco) was added to each sample. NeuN-488 (1:500; 
Abcam) was added and samples were incubated 45 min at 4°C with gentle mixing. Immediately 
prior to flow cytometry sorting, nuclei were stained with 7-AAD (Thermo Fisher Scientific) and 
passed through a 30 μM filter (SystemX). Nuclei positive for 7-AAD and either NeuN+ 
(neuronal) or NeuN‒ (non-neuronal) were sorted using a MoFlo Astrios (Beckman Coulter) 
running Summit 6.3 by the Van Andel Research Institute Flow Cytometry Core. Approximately 
1 million NeuN+ nuclei were sorted for each sample. NeuN+ sample purity (~96%) was 
confirmed by reanalysis on the sorter, and was confirmed by RNA analysis showing an 
enrichment of neuronal markers in the NeuN+ (but not NeuN‒) fraction (Supplementary Fig. 1). 
Immediately, after sorting nuclei were placed on ice and then precipitated with 0.3 M sucrose, 





supernatant was removed from NeuN+ and NeuN‒ samples and pellets were stored at -80°C. 
Genomic DNA from each sample’s NeuN+ fraction was isolated using standard phenol-
chloroform extraction methods. 
 
DNA methylation analysis comparison 
We compared our findings with existing packages for DNA methylation analysis. We used 
DMRseq7 to detect genomic regions with DNA methylation changes associated with increasing 
Braak stage pathology (parameters: % methylation cutoff=0.001; cytosine minimum per 
region=3), adjusting for age, sex, postmortem interval, and neuronal subtype proportion. We 
found a strong correlation between the results of DMRseq and our analysis (p<10-15, Pearson's 
correlation). 
 
Enhancer DNA methylation association with RNA levels  
We examined our DNA methylation and corresponding RNA-seq data (n=25 individuals) to 
determine whether there was a relationship between DNA methylation changes with AD 
pathology and mRNA level changes with AD pathology. First, we determined the average DNA 
methylation at each enhancer region. Enhancers were matched to their respective target genes 
(determined from the chromatin conformation analysis described above). We then determined 
the Pearson’s correlation between residual DNA methylation status change with AD Braak stage 
(adjusted for age, sex, postmortem interval, and neuronal subtype) and residual mRNA level 
change with AD Braak stage (adjusted for sex, age, postmortem interval, neuronal proportion, 





evaluated for enhancers previously identified to be differentially methylated in AD (significant 
DMR) or enhancers unchanged in AD (non-significant DMR). 
 
eRNAs are non-coding transcripts expressed from enhancers, whose expression has been 
previously shown to correlate with enhancer activation and mRNA expression of the target 
gene8. Our RNA-seq data (n=25 individuals) was also used to profile eRNA expression from 
enhancer regions identified in our previous DNA methylation analysis. These enhancer regions 
were combined with the Gencode v19 primary assembly annotation to create a new 
transcriptome annotation file. STAR9 (v2.3.5a) index was generated using Ensemble GRCh37 
p13 primary assembly genome and this new transcriptome annotation. Read alignment, counting 
and trimmed mean of M-values normalization was performed as previously stated10. Lowly 
expressed genes and eRNAs were filtered (FPKM < 0.01) as previously published10. We 
identified eRNA expression at 2,563 brain enhancers. A robust linear model examining AD 
Braak stage and adjusting for age, sex, postmortem interval, neuronal cell composition, and RIN 
with empirical Bayes, was performed to identify differentially expressed eRNAs and genes, 
followed by Benjamini-Hochberg multiple testing correction (statistical significance q<0.05). 
Hypergeometric testing was used to determine whether differentially expressed eRNAs in AD 
were enriched at enhancer regions with differential methylation in AD. 
 
We examined in our DNA methylation and RNA-seq data (n=25 individuals) the relationship 
between methylation at DSCAML1 enhancers and BACE1 mRNA expression. For this, we 
compared DNA methylation in AD-relevant DSCAML1 enhancers found to target BACE1 in the 





adjusting for sex, age, postmortem interval, neuronal proportion, and RIN (Supplementary Table 
8). 
 
Validation in independent datasets 
We used data from the Religious Orders Study (ROS) and The Memory and Aging Project 
(MAP)11 (Synapse ID: syn3219045 [https://www.synapse.org/#!Synapse:syn3219045]). All 
individuals used in this analysis had a clinical diagnosis of unaffected/control or AD. 
 
RNA-seq data (Synapse ID: syn3388564 [https://www.synapse.org/#!Synapse:syn3388564]) was 
obtained for 338 control and AD prefrontal cortex samples. RNA isolation, sequencing, and data 
preprocessing (including quantile normalization and Combat12 to remove batch effects) was 
performed by the ROSMAP as described in detail in refs13, 14. Low expressed genes were 
removed (FPKM < 0.5 in more than 30% of samples). We then applied a robust linear regression 
using limma15 with Braak stage as the independent variable, log2 transformed FPKM values as 
the dependent variable, and age, sex, postmortem interval, neuronal cell proportion, and RIN 
(verified by TIN) as covariates. Differentially expressed genes were selected after Benjamini-
Hochberg correction for multiple testing (q<0.05). 
 
DNA methylation array (Synapse ID: syn3157275 
[https://www.synapse.org/#!Synapse:syn3157275]) data generated by Illumina 
HumanMethylation450 BeadChip was used to examine the effects of DSCAML1 intron 3 
methylation on BACE1 expression (177 AD samples with DNA methylation array and RNA-seq, 





samples with DNA methylation array and pathological/cognitive testing). Detailed information 
on DNA methylation data collection from the human prefrontal cortex for the ROSMAP study is 
provided in ref16.  DNA methylation array batch effects were removed by Combat12. First, we 
examined the correlation between DNA methylation at cg07533617 (or averaged DSCAML1 
intron 3 methylation) and BACE1 gene expression, after adjusting for age, sex, postmortem 
interval, years of education, neuronal cell proportion, and RIN, using a robust linear regression 
by limma15, 17. Next, we determined the relationship between DNA methylation status at 
DSCAML1 intron 3 and AD pathology. Uniform assessment of AD pathology, including β-
amyloid and tangles, had been conducted for ROSMAP samples as previously described18, 19. We 
used robust linear regressions by limma15, 17, adjusting for age, sex, postmortem interval, years of 
education, and neuronal cell proportion, to determine the association between DNA methylation 
at cg07533617 (or averaged DSCAML1 intron 3 methylation) and pathological variables: 
amyloid level and neurofibrillary tangle density. Finally, we determined whether DNA 
methylation at DSCAML1 intron 3 was linked to the progression of cognitive decline. 
Participants in the ROSMAP study had undergone comprehensive annual cognitive assessments 
for many years, as previously described20. Annual composite scores for global cognitive 
function, as well as summary measures for episodic memory (7 tests), semantic memory (3 
tests), working memory (3 tests), processing speed (2 tests), and visuospatial ability (2 tests) 
were used (total of 6 cognitive domains)20. We used a linear mixed model to examine the 
relationship between DNA methylation at cg07533617 (or averaged DSCAML1 intron 3 
methylation) and the rate of decline in each cognitive domain. The model used annual cognitive 
scores as continuous longitudinal outcomes and included the factors of DNA methylation level, 





for each person. The model was adjusted for age, sex, years of education, postmortem interval, 
and neuronal cell proportion. The models employed in this study are analogous to those used in 
other studies involving pathological/clinical ROSMAP data15, 17. 
 
To further examine the influence of enhancers within DSCAML1 intron 3 on BACE1 expression, 
we performed an analysis examining the relationship between cis-acting haplotypes and BACE1 
transcript levels in controls and AD patients. For this analysis, we used imputed genotype data 
that was obtained from the ROSMAP study (Synapse ID:  syn3157329 
[https://www.synapse.org/#!Synapse:syn3157329]). There were 278 AD patients and controls 
with both genotype and RNA-seq data in the ROSMAP. As described21, only individuals of 
European ancestry were included in this analysis to minimize population heterogeneity. The 
sample-level quality control criteria excluded samples that had a genotype success rate below 
95%, a discordance between inferred and reported sex, and excess inter/intraheterozygosity. The 
SNP-level quality control criteria excluded SNPs with Hardy-Weighberg equilibrium (p<0.001), 
MAF < 0.01, genotype call rate < 0.95, mishap test < 1x10-9. Population outliers were removed 
using EIGENSTRAT22 with default parameters. We performed a cis-haplotype analysis on the 
extended BACE1 genomic area (± 500 kb centered on BACE1 and including the DSCAML1 
gene); this analysis involved 5,533 SNPs from which there were 53 haplotypes identified by 
Haploview23 (with 2 or more SNPs per haplotype). Gene expression values for all genes were 
normalized for eQTL analysis using the following procedure: 1) Low expressed genes were 
removed (FPKM < 0.5 in more than 30% of samples); 2) The distribution of FPKMs in each 
sample was quantile normalized to the average empirical distribution observed across all 





assess the effect of genotype on BACE1 expression, with sex, age, postmortem interval, Braak 
stage, years of education, neuronal cell proportion, and RIN as covariates. Then we generated a 
combined p value for SNPs within each haplotype using the Fisher's method24. Benjamini-
Hochberg method was used for false discovery rate control. This analysis was repeated to 
examine whether cis-acting genetic variation in DSCAML1 intron 3 affected the transcript levels 
of nearby cis-genes: BACE1, CEP164, and DSCAML1 (chr11:117,000,000-117,800,000, 
genomic area centered on DSCAML1 intron 3). This analysis involved 4,305 SNPs from which 
34 haplotypes were determined by Haploview23 (with 2 or more SNPs per haplotype). 
Benjamini-Hochberg adjustment for multiple testing was applied to the combined p values for 
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